South Africa T-cell Therapy Market Size & Outlook
South Africa t-cell therapy market, 2018-2028 (US$M)
Related Markets
South Africa t-cell therapy market highlights
- The South Africa t-cell therapy market generated a revenue of USD 47.2 million in 2021 and is expected to reach USD 79.0 million by 2028.
- The South Africa market is expected to grow at a CAGR of 7.6% from 2022 to 2028.
- In terms of segment, commercialized was the largest revenue generating modality type in 2021.
- Commercialized is the most lucrative modality type segment registering the fastest growth during the forecast period.
T-cell therapy market data book summary
| Market revenue in 2021 | USD 47.2 million |
| Market revenue in 2028 | USD 79.0 million |
| Growth rate | 7.6% (CAGR from 2021 to 2028) |
| Largest segment | Commercialized |
| Fastest growing segment | Commercialized |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Commercialized |
| Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, South Africa accounted for 0.7% of the global t-cell therapy market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In Middle East & Africa, South Africa t-cell therapy market is projected to lead the regional market in terms of revenue in 2028.
- South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 79.0 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
T-cell Therapy Market Scope
T-cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
South Africa t-cell therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 100% in 2021. Horizon Databook has segmented the South Africa t-cell therapy market based on commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
Significant R&D has been conducted in South Africa to boost development of immunotherapies. Although no commercial products have been approved by the country, the number of clinical trials has increased to boost commercialization of these products.
Some of the challenges being faced by the country in introducing T-cell therapies are manufacturing restraints, underdevelopment of regulatory systems, legal & social requirements, and high pricing of these therapies. Private investment coupled with government funding could prove to be effective for introducing these therapies in South Africa.
Reasons to subscribe to South Africa t-cell therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of South Africa t-cell therapy market databook
-
Our clientele includes a mix of t-cell therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa t-cell therapy market , including forecasts for subscribers. This country databook contains high-level insights into South Africa t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
South Africa t cell therapy market size, by modality type, 2018-2028 (US$M)
South Africa T-cell Therapy Market Outlook Share, 2021 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
